<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196442</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13098</org_study_id>
    <secondary_id>NCI-2010-01945</secondary_id>
    <nct_id>NCT01196442</nct_id>
  </id_info>
  <brief_title>Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer</brief_title>
  <official_title>An Expanded Trial of MC5-A Calmare Therapy in the Treatment of Cancer Pain Syndromes and Chronic Chemotherapy-Induced Peripheral Neuropathy Including Pain and Numbness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Electrical stimulation pain therapy may help relieve chronic pain and numbness&#xD;
      caused by chemotherapy. PURPOSE: This pilot trial studies electrical stimulation pain therapy&#xD;
      in treating chronic pain and numbness caused by chemotherapy in patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the effect of MC5-A on pain symptoms both immediately and over time.&#xD;
&#xD;
      II. To evaluate the effect of Calmare therapy on other non-pain symptoms. III. To evaluate&#xD;
      the effect of MC5-A on daily opioid and other pain medication use.&#xD;
&#xD;
      OUTLINE: Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy&#xD;
      over 30 minutes once daily for 10 days. After completion of study treatment, patients are&#xD;
      followed up for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Score From Day 1 to Day 10</measure>
    <time_frame>From day 1 to day 10</time_frame>
    <description>Change in Brief Pain Inventory (Now)Scale&#xD;
1 (none) to 5 (complete interference)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Electrical Stimulation Pain Therapy on Other Non-pain Symptoms at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Medications Including Morphine Oral Dose Equivalents, Anti-depressants, and Neuroleptics</measure>
    <time_frame>From day 1 to day 30</time_frame>
    <description>Record daily pain medication usage and convert all opioids to MOEDs (American Pain Society 2003). Compare the average daily use prior to day 1 to the average daily use day 30. Range is 0-none to 240-most</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 1</measure>
    <time_frame>month 1</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy n Other Non-pain Symptoms at Month 2</measure>
    <time_frame>month 2</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Cancer-related Problem/Condition</condition>
  <condition>Neurotoxicity</condition>
  <condition>Pain</condition>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Arm I electric stimulation pain therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electrical stimulation pain therapy</intervention_name>
    <description>Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10</description>
    <arm_group_label>Arm I electric stimulation pain therapy</arm_group_label>
    <other_name>Calmare</other_name>
    <other_name>analgesia</other_name>
    <other_name>cancer pain management</other_name>
    <other_name>management of cancer pain</other_name>
    <other_name>pain management</other_name>
    <other_name>therapy, pain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months</description>
    <arm_group_label>Arm I electric stimulation pain therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CIPN neuropathy: received, or currently receiving, neurotoxic chemotherapy (including&#xD;
             taxanes-such as paclitaxel or docetaxel, or platinum-based compounds such as&#xD;
             carboplatin or cis-platinum or oxaliplatin, or vinca alkaloids such as vincristine,&#xD;
             vinblastine, or vinorelbine, or proteosome inhibitors such as bortezomib)&#xD;
&#xD;
          -  Pain or symptoms of peripheral neuropathy of &gt;= 1 months duration attributed to&#xD;
             chemotherapy-induced peripheral neuropathy&#xD;
&#xD;
          -  OR pain of the other types including chemotherapy-induced peripheral neuropathy,&#xD;
             numbness predominant; post mastectomy pain; post surgical pain; post herpetic&#xD;
             neuropathy; post radiation pain; other (vertebral compression, fracture,&#xD;
             miscellaneous)&#xD;
&#xD;
          -  The pain must have been stable for at least 2 weeks&#xD;
&#xD;
          -  An average daily pain rating of &gt;= 5 out of 10, using the pain numerical rating scale&#xD;
             (NRS: 0 is no pain and 10 is worst pain possible); or numbness that bothers the&#xD;
             patient at least &quot;a little bit&quot; on the CIPN-20&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months&#xD;
&#xD;
          -  ECOG performance status 0, 1, or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, nursing women, women of childbearing potential or their sexual&#xD;
             partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth&#xD;
             control pills, injections, intrauterine device [IUD], surgical sterilization,&#xD;
             subcutaneous implants, abstinence, etc.)&#xD;
&#xD;
          -  Use of an investigational agent for pain control concurrently or =&lt; 30 days&#xD;
&#xD;
          -  History of an allergic reaction or previous intolerance to transcutaneous electronic&#xD;
             nerve stimulation&#xD;
&#xD;
          -  Patients with implantable drug delivery systems, e.g., Medtronic Synchromed&#xD;
&#xD;
          -  Patients with heart stents or metal implants such as pacemakers, automatic&#xD;
             defibrillators, aneurysm clips, vena cava clips and skull plates (metal implants for&#xD;
             orthopedic repair, e.g., pins, clips, plates, cages, joint replacements are allowed)&#xD;
&#xD;
          -  Patients with a history of myocardial infarction or ischemic heart disease within the&#xD;
             past six months&#xD;
&#xD;
          -  Patients with history of epilepsy, brain damage, use of anti-convulsants, symptomatic&#xD;
             brain metastases&#xD;
&#xD;
          -  Prior celiac plexus block, or other neurolytic pain control treatment within 4 weeks&#xD;
&#xD;
          -  Other identified causes of painful paresthesias existing prior to chemotherapy (e.g.,&#xD;
             radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing&#xD;
             peripheral neuropathy of another etiology: B12 deficiency, AIDS, monoclonal&#xD;
             gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or&#xD;
             hypothyroidism, inherited neuropathy)&#xD;
&#xD;
          -  Skin conditions such as open sores that would prevent proper application of the&#xD;
             electrodes&#xD;
&#xD;
          -  Other medical or other condition(s) that in the opinion of the investigators might&#xD;
             compromise the objectives of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Swainey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massey.vcu.edu/</url>
    <description>VCU Massey Cancer Center</description>
  </link>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>October 11, 2012</results_first_submitted>
  <results_first_submitted_qc>January 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2013</results_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 08/30/2010 through 06/11/2012 at a medical clinical</recruitment_details>
      <pre_assignment_details>No pre-assignment criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MC5A Calmare Therapy</title>
          <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MC5A Calmare Therapy</title>
          <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Score From Day 1 to Day 10</title>
        <description>Change in Brief Pain Inventory (Now)Scale&#xD;
1 (none) to 5 (complete interference)</description>
        <time_frame>From day 1 to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
Electrical stimulation pain therapy: Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
Questionnaire administration: Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score From Day 1 to Day 10</title>
          <description>Change in Brief Pain Inventory (Now)Scale&#xD;
1 (none) to 5 (complete interference)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electrical Stimulation Pain Therapy on Other Non-pain Symptoms at Day 1</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants at Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electrical Stimulation Pain Therapy on Other Non-pain Symptoms at Day 1</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <population>Participants at Day 1</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4129" spread="0.9114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6268" spread="0.7598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Medications Including Morphine Oral Dose Equivalents, Anti-depressants, and Neuroleptics</title>
        <description>Record daily pain medication usage and convert all opioids to MOEDs (American Pain Society 2003). Compare the average daily use prior to day 1 to the average daily use day 30. Range is 0-none to 240-most</description>
        <time_frame>From day 1 to day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Medications Including Morphine Oral Dose Equivalents, Anti-depressants, and Neuroleptics</title>
          <description>Record daily pain medication usage and convert all opioids to MOEDs (American Pain Society 2003). Compare the average daily use prior to day 1 to the average daily use day 30. Range is 0-none to 240-most</description>
          <units>doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Day 10</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Day 10</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8305" spread="0.9437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1815" spread="0.7878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 1</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 1</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>snesory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5207" spread="0.9345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5443" spread="0.7797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy n Other Non-pain Symptoms at Month 2</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>month 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy n Other Non-pain Symptoms at Month 2</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4723" spread="0.9480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3816" spread="0.7917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 3</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 3</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3325" spread="0.9388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8499" spread="0.7835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While patients are active in trial: During 10 days of treatment and followed for 3 months after treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MC5A Calmare Therapy</title>
          <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.&#xD;
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10&#xD;
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <description>Unrelated (Grade 2)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Craig W. Swainey</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-9723</phone>
      <email>cswainey@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

